BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32581519)

  • 1. Analysis of Patient Preferences in Lung Cancer - Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects.
    Janssen EM; Dy SM; Meara AS; Kneuertz PJ; Presley CJ; Bridges JFP
    Patient Prefer Adherence; 2020; 14():927-937. PubMed ID: 32581519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment.
    Janse S; Janssen E; Huwig T; Basu Roy U; Ferris A; Presley CJ; Bridges JFP
    Curr Med Res Opin; 2021 Apr; 37(4):643-653. PubMed ID: 33571024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis.
    Bridges JF; Mohamed AF; Finnern HW; Woehl A; Hauber AB
    Lung Cancer; 2012 Jul; 77(1):224-31. PubMed ID: 22369719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician preferences for chemotherapy in the treatment of non-small cell lung cancer in China: evidence from multicentre discrete choice experiments.
    Sun H; Wang H; Shi L; Wang M; Li J; Shi J; Ni M; Hu X; Chen Y
    BMJ Open; 2020 Feb; 10(2):e032336. PubMed ID: 32051302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China.
    Sun H; Wang H; Xu N; Li J; Shi J; Zhou N; Ni M; Hu X; Chen Y
    Patient Prefer Adherence; 2019; 13():1701-1709. PubMed ID: 31631985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternatives.
    Oliveri S; Lanzoni L; Veldwijk J; de Wit GA; Petrocchi S; Janssens R; Schoefs E; Smith MY; Smith I; Nackaerts K; Vandevelde M; Louis E; Decaluwé H; De Leyn P; Declerck H; Petrella F; Casiraghi M; Galli G; Garassino MC; Girvalaki C; Huys I; Pravettoni G
    Front Psychol; 2023; 14():1062830. PubMed ID: 37425173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment.
    Liu F; Hu H; Wang J; Chen Y; Hui S; Hu M
    Front Public Health; 2021; 9():653450. PubMed ID: 33842426
    [No Abstract]   [Full Text] [Related]  

  • 8. Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment.
    Meirelles I; Magliano C
    Patient Prefer Adherence; 2021; 15():911-917. PubMed ID: 33958859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
    Mansfield C; Botha W; Vondeling GT; Klein K; Wang K; Singh J; Hackshaw MD
    Breast Cancer; 2023 Jan; 30(1):23-35. PubMed ID: 36074320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient preferences in advanced or recurrent ovarian cancer.
    Havrilesky LJ; Alvarez Secord A; Ehrisman JA; Berchuck A; Valea FA; Lee PS; Gaillard SL; Samsa GP; Cella D; Weinfurt KP; Abernethy AP; Reed SD
    Cancer; 2014 Dec; 120(23):3651-9. PubMed ID: 25091693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer.
    Bridges JF; la Cruz M; Pavilack M; Flood E; Janssen EM; Chehab N; Fernandes AW
    Future Oncol; 2019 Dec; 15(34):3895-3907. PubMed ID: 31621403
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment.
    Wong XY; Lim AQJ; Shen Q; Chia JWK; Chew MH; Tan WS; Wee HL
    Curr Med Res Opin; 2020 Oct; 36(10):1677-1686. PubMed ID: 32609014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits.
    Richardson DR; Crossnohere NL; Seo J; Estey E; O'Donoghue B; Smith BD; Bridges JFP
    Cancer Epidemiol Biomarkers Prev; 2020 May; 29(5):942-948. PubMed ID: 32132149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The perspective of women with an increased risk of OHSS regarding the safety and burden of IVF: a discrete choice experiment.
    Braam SC; de Bruin JP; Mol BWJ; van Wely M
    Hum Reprod Open; 2020; 2020(2):hoz034. PubMed ID: 32123754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
    Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
    Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    Havrilesky LJ; Lim S; Ehrisman JA; Lorenzo A; Alvarez Secord A; Yang JC; Johnson FR; Gonzalez JM; Reed SD
    Gynecol Oncol; 2020 Mar; 156(3):561-567. PubMed ID: 31982178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor-mutant non-small cell lung cancer.
    Hata A; Fifer S; Hasegawa K; Ando E; Kasahara-Kiritani M; Takahashi M; Ordman R; Toh L; Inoue A
    Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38196301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Women's perspectives on ovulation induction with or without IUI as treatment for normogonadotrophic anovulation: a discrete choice experiment.
    Weiss NS; Schreurs AMF; van der Veen F; Hompes PGA; Lambalk CB; Mol BW; van Wely M
    Hum Reprod Open; 2017; 2017(3):hox021. PubMed ID: 30895235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma.
    Postmus D; Richard S; Bere N; van Valkenhoef G; Galinsky J; Low E; Moulon I; Mavris M; Salmonsson T; Flores B; Hillege H; Pignatti F
    Oncologist; 2018 Jan; 23(1):44-51. PubMed ID: 29079638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of information on preferences for treatments of metastatic renal cell carcinoma.
    Mansfield C; Srinivas S; Chen C; Hauber AB; Hariharan S; Matczak E; Sandin R
    Curr Med Res Opin; 2016 Nov; 32(11):1827-1838. PubMed ID: 27404275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.